MSD - Articles and news items

FDA approves Merck’s bladder cancer drug

Industry news / 24 May 2017 / Niamh Marriott, Junior Editor

The FDA has approved two new indications for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for bladder cancer…

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

Sanofi Pasteur and MSD end joint vaccines business in Europe

Industry news / 3 January 2017 / Niamh Louise Marriott, Digital Editor

Sanofi and its vaccines business unit Sanofi Pasteur will end their vaccine joint-venture with MSD (known as Merck in the US and Canada) – SPMSD…

MSD’s Hepatitis C drug given green light for EU market

Industry news / 9 August 2016 / MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with genotype 1 and 4 infection…

MSD announces positive results from elbasvir/grazoprevir HCV study

Industry news / 14 April 2016 / Victoria White, Digital Content Producer

Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV…

MSD presents data from Simponi GO-COLITIS trial

Industry news / 21 March 2016 / Victoria White

GO-COLITIS evaluated the efficacy of Simponi (golimumab) in inducing and maintaining clinical response in patients with moderate to severe ulcerative colitis…

Sanofi Pasteur and MSD to end joint vaccines operations in Europe

Industry news / 8 March 2016 / Victoria White

Upon concluding their joint venture, Sanofi Pasteur and MSD plan to integrate their respective European vaccine businesses into their operations…

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

NICE recommends 7 DMARDs for severe rheumatoid arthritis

Industry news / 26 January 2016 / Victoria White

NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs…

Pembrolizumab improves survival in PD-L1 expressing NSCLC

Industry news / 21 December 2015 / Victoria White

MSD has announced results from the Phase 2/3 KEYNOTE-010 study of Keytruda (pembrolizumab) in patients with previously treated non-small cell lung cancer (NSCLC)…

SMC accepts Keytruda as a treatment option for advanced melanoma

Industry news / 10 November 2015 / Victoria White

The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)…

Another NICE recommendation for melanoma drug Keytruda

Industry news / 9 October 2015 / Victoria White

This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...